Hematologic Malignancy
Chronic Lymphocytic Leukemia
CI-CAN-00002362BCLL · CLLExplore in graph →
Hematologic265 active trials6 approved drugs46 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002362BCLL · CLLExplore in graph →
Clinical trials
1,256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (239)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01650727 | A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | completed | Phase 1 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 10, 2015 | clinicaltrials |
| NCT01310101 | Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 33 | Brno University HospitalOTHER | 1 | Feb 3, 2015 | clinicaltrials |
| NCT02136511 | Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | approved for marketing | — | — | Gilead SciencesINDUSTRY | 4 | Oct 28, 2014 | clinicaltrials |
| NCT01465230 | Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia | terminated | Phase 2 | 2 | Yale UniversityOTHER | 1 | Oct 23, 2014 | clinicaltrials |
| NCT02267590 | Tissue Collection for Biomarkers Determining Resistance to Ibrutinib(CLARITY) | unknown | — | 120 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT00230282 | Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 25 | Steven E. CoutreOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | terminated | N/A | 10 | Indiana UniversityOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00569842 | Investigation of the Cylex® ImmuKnow® Assay | completed | — | 45 | Indiana UniversityOTHER | 1 | Sep 11, 2014 | clinicaltrials |
| NCT02117336 | Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | suspended | Phase 1 | 36 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00621452 | Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2014 | clinicaltrials |
| NCT01292135 | Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 33 | Pharmacyclics LLC.INDUSTRY | 1 | Jul 24, 2014 | clinicaltrials |
| NCT01557777 | Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 17 | AbbVie (prior sponsor, Abbott)INDUSTRY | 5 | Jul 4, 2014 | clinicaltrials |
| NCT00754650 | A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia | completed | Phase 2 | 2 | Hoffmann-La RocheINDUSTRY | 1 | Jun 26, 2014 | clinicaltrials |
| NCT02156726 | Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project(Q-lite) | unknown | — | 200 | Czech CLL Study GroupNETWORK | 1 | Jun 5, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00828282 | High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL | completed | Phase 1 | 3 | John HaslipOTHER | 1 | May 26, 2014 | clinicaltrials |
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 27 | Pharmacyclics LLC.INDUSTRY | 1 | May 23, 2014 | clinicaltrials |
| NCT00290472 | CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00183950 | Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy | terminated | Phase 1 / Phase 2 | 12 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00098670 | Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00398112 | Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00600964 | A Phase I/II Study of GX15-070MS in Untreated CLL | completed | Phase 1 | 26 | Gemin XINDUSTRY | 2 | May 12, 2014 | clinicaltrials |
| NCT00290810 | Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00303966 | Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 7, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT01161511 | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | completed | Phase 1 | 27 | Xencor, Inc.INDUSTRY | 1 | Apr 21, 2014 | clinicaltrials |
| NCT01246557 | Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment(LENDEX-LLC-09) | completed | Phase 1 / Phase 2 | 20 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Apr 4, 2014 | clinicaltrials |
| NCT01233921 | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer | completed | N/A | 6 | Martin, PaulOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT01105247 | Safety of PCI-32765 in Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 133 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 31, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00086580 | Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients | completed | Phase 3 | 335 | Genzyme, a Sanofi CompanyINDUSTRY | 15 | Mar 13, 2014 | clinicaltrials |
| NCT00328198 | Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 86 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Mar 13, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00919321 | The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL(KLL2) | completed | Phase 4 | 32 | Tampere University HospitalOTHER | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01841489 | A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics | completed | Phase 1 | 56 | Gilead SciencesINDUSTRY | 1 | Feb 7, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 | clinicaltrials |
| NCT00458679 | Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells(PRIMAL) | completed | Phase 1 | 6 | Baylor College of MedicineOTHER | 1 | Feb 3, 2014 | clinicaltrials |
| NCT00439231 | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 33 | Georg Aue, M.D.NIH | 1 | Jan 13, 2014 | clinicaltrials |
| NCT01251250 | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jan 13, 2014 | clinicaltrials |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | terminated | Phase 2 | 16 | Marshall UniversityOTHER | 1 | Dec 12, 2013 | clinicaltrials |
| NCT00836043 | Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia | terminated | — | 6 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Dec 3, 2013 | clinicaltrials |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | terminated | Phase 2 | 1 | Texas Oncology Cancer CenterINDUSTRY | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00006226 | Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00068315 | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00079378 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Feb 10, 2015source: clinicaltrials